key: cord-0007218-2s3b82l3 authors: Simner, Patricia J; Miller, Steven; Carroll, Karen C title: Understanding the Promises and Hurdles of Metagenomic Next-Generation Sequencing as a Diagnostic Tool for Infectious Diseases date: 2018-03-01 journal: Clin Infect Dis DOI: 10.1093/cid/cix881 sha: bd6ff668b291b07c039010c27d1465777647f60f doc_id: 7218 cord_uid: 2s3b82l3 Agnostic metagenomic next-generation sequencing (mNGS) has emerged as a promising single, universal pathogen detection method for infectious disease diagnostics. This methodology allows for identification and genomic characterization of bacteria, fungi, parasites, and viruses without the need for a priori knowledge of a specific pathogen directly from clinical specimens. Although there are increasing reports of mNGS successes, several hurdles need to be addressed, such as differentiation of colonization from infection, extraneous sources of nucleic acid, method standardization, and data storage, protection, analysis, and interpretation. As more commercial and clinical microbiology laboratories develop mNGS assays, it is important for treating practitioners to understand both the power and limitations of this method as a diagnostic tool for infectious diseases. Infectious diseases remain leading causes of morbidity and mortality among all patient populations worldwide [1] . The spread of multidrug-resistant pathogens such as Candida auris and carbapenemase-producing gram-negative organisms and the reemergence of Ebola and Zika viruses highlight the ongoing challenges with diagnosis and management of patients with infectious diseases. Accurate diagnosis can be challenging due to a wide variety of pathogens causing clinically indistinguishable diseases. Current methods, such as culture, nucleic acid amplification tests, and serologic assays, generally require the use of a battery of tests to attempt to establish a diagnosis. Often times these methods still rely on a growth amplification step of viable microorganisms in culture for identification and antimicrobial susceptibility testing that take a minimum of 48 hours for commonly encountered pathogens and longer for more fastidious organisms (up to weeks for more insidious pathogens such as fungi and mycobacteria). Novel technologies such as syndromic multiplex polymerase chain reaction (PCR) panels, 16S ribosomal DNA (16S rDNA) Sanger sequencing, and matrix-assisted laser desorption/ionization-time-of-flight mass spectrometry (MALDI-TOF MS) have decreased turnaround times and subsequently beneficially impacted patient care [2] . Despite these advances, the etiology of infectious diseases remains unknown in up to 60% of cases depending on the clinical syndrome [3, 4] . Missed diagnoses due to the limitations of current microbiologic methodologies drive the use of empiric broad-spectrum antibiotics preventing the use of targeted, curative therapies. Recent advances and lower costs of next-generation sequencing (NGS) technologies, more rapid, user-friendly data analysis tools, and the creation of accurate, comprehensive databases has allowed for NGS applications to cross the divide from microbial research to diagnostic microbiology [4] . One such application, unbiased metagenomic next-generation sequencing (mNGS), has the capability to overcome limitations of current diagnostic tests allowing for hypothesis-free, culture-independent, pathogen detection directly from clinical specimens. This method allows for universal pathogen detection regardless of the type of microbe (viruses, bacteria, fungi, and parasites) and can even be applied for novel organism discovery, potentially enabling replacement of many targeted pathogen tests with a single mNGS assay ( Figure 1 ). As the availability of mNGS clinical diagnostic tests increases, it is important for treating practitioners to understand both its strengths and limitations as a tool for infectious disease diagnostics. Next-generation sequencing technologies allow for sequencing of multiple individual DNA molecules in parallel regardless of composition, generating millions to billions of reads per instrument run. Reads are the basic element produced by DNA sequencing that are composed of a series of sequential bases (adenine, guanine, thymine, and cytosine) making up the DNA fragment, which can vary in size from small reads (75-600 bp) to long reads (1000-10 000s bp) depending on the sequencing technology. NGS overcomes many of the limitations of traditional Sanger sequencing, which requires targeted sequencing (preamplification of a known target, such as 16S rDNA) of a uniform or low-diversity sample (the sample ideally is composed of a single organism or a maximum of 3 organisms). The most common applications of NGS in diagnostic microbiology laboratories ( Figure 2 ) include (1) whole-genome sequencing (sequencing and assembly of the genome of a pathogen of interest [eg, evaluating genetic relatedness during outbreak investigations, identification of new species]) [5] [6] [7] ; (2) targeted NGS with different methods for enrichment including amplification or probe hybridization (ie, 16S rDNA bacterial profiling or PCR amplification of other specified targets followed by NGS) [7, 8] ; or (3) mNGS (defined in more detail below) [9] . We refer the reader to other publications on this topic that summarize common terms and approaches used in DNA sequence analysis [10] , the different NGS technologies [11] [12] [13] , and the various NGS methods, bioinformatics tools [14] and clinical applications [10, 15] . This review will focus on mNGS for infectious disease diagnostic pathogen detection. Other applications of mNGS testing directly from specimens that are also not covered in this review include antimicrobial resistance gene and virulence gene detection, strain typing, and host immune response profiling [16] . mNGS, also known as unbiased or agnostic NGS or clinical metagenomics, is a method where all the nucleic acid (DNA and/ or RNA) of a specimen is sequenced in parallel. This results in isolation and amplification of both host and pathogen nucleic acid sequenced from the specimen (Figure 2 ). Additional sources of nucleic acid that may be concurrently sequenced include nucleic acid introduced at the time of collection, within collection tubes, from the environment, and in sequencing reagents. Due to these complexities and potential breadth of detection, interpretation of mNGS results directly from clinical specimens can be difficult and requires careful interpretation and consideration. HOST NUCLEIC ACID AMPLIFICATION: A BURDEN OR AN ADVANTAGE? As the majority of a specimen is of human origin and the human genome is much larger than that of microorganisms (1000 times larger than bacterial genomes), the results from mNGS from clinical specimens typically generate >99% host Figure 1 . Summary of the traditional timeline and workflow in diagnostic medical microbiology laboratories and the future state with the incorporation of metagenomic next-generation sequencing (mNGS) methodologies. Current organism detection techniques (orange), identification (yellow), antimicrobial susceptibility testing (green), and strain typing (purple) can take up to a week or longer from specimen collection (blue) to strain typing results. mNGS has the capability of greatly reducing turnaround times and providing all the data summarized in current methods in a single modality (red) and could potentially provide all of these within 24-48 hours of specimen receipt. To date, the available evidence is poor to use antibiotic resistance gene detection to predict phenotypic antimicrobial susceptibility testing profiles for clinical care [16] . Abbreviations: AFB, acid-fast bacilli; cDNA, complementary DNA; CSF, cerebrospinal fluid; KOH, potassium hydroxide; MALDI-TOF MS, matrix-assisted laser desorption/ionization-timeof-flight mass spectrometry; MLST, multilocus sequence typing; mNGS, metagenomic next-generation sequencing; PCR, polymerase chain reaction; PFGE, pulsed-field gel electrophoresis; 16S rDNA, 16S ribosomal DNA. reads [17] . Successful clinical applications of mNGS have demonstrated that 0.00001%-0.7% of total reads (10 to tens of thousands of pathogen reads out of a total of millions of reads) have been used to make successful diagnoses (Table 1 , mNGS results column). Pathogen reads make up a minute fraction of the sequencing results. Host nucleic acid can be depleted [18] or, if pathogen reads are enriched, more microorganism reads can be generated to more confidently provide a diagnosis and allow for increased analytical sensitivity (limit of detection). Additionally, if a robust immune response is generated in response to the pathogen, the specimen will contain a high concentration of leukocytes, further contributing to host nucleic acid in the sample and further limiting pathogen detection. Thus, the higher the sequencing depth (the higher number of reads generated/specimen) of the method, the higher the likelihood that the pathogen will be sequenced and detected (more reads equals higher sensitivity). For a conceptual illustration of how cellularity and overall nucleic acid affect analytic sensitivity, see Figure 1 in Schlaberg et al [4] . One potential advantage of sequencing amplified host nucleic acid is the opportunity to evaluate the host immunologic response associated with the presence and type of infection. This can include the presence of gene biomarkers associated with an antiviral or antibacterial response (specific expression of cytokines, chemokines, interferons, etc), genes involved in signaling pathways, and adaptive immunity. These biomarkers can provide insight into the pathogenesis of the microorganisms detected [19] . Detection of microorganisms in clinical samples by mNGS can reflect normal microbiota, transient colonizers, sample contamination, and/or infection. Initial applications of mNGS focused on detection of pathogens in normally sterile specimens, such as cerebrospinal fluid (CSF) and brain biopsies, simplifying the assignment of clinical significance for detected organisms [17, [20] [21] [22] [23] . That being said, even body sites that are considered normally "sterile" may contain a microbiome, which can be defined and detected by deep sequencing [24] . Reports in the literature are now showing applications from other specimen types where normal microbiota can further complicate interpretation of results, such as respiratory specimens [19, 25] . These methods will likely require further studies to determine the best approach to distinguish colonization from infection. Currently, mNGS is only able to quantify pathogen reads as a percentage of the total number of sequence reads. Clinical microbiology laboratories have developed procedures throughout the years to distinguish true pathogens from colonizers in cultures, and similar Targeted amplification of 16S rDNA from a clinical specimen for bacterial profiling. C, Metagenomic next-generation sequencing from clinical specimens. The nucleic acid composition of the specimens includes host (black), microbiome and pathogen detection (blue, green, and red), and last, the introduction of contaminating nucleic acid (orange). Analysis of reads generally involves removing host DNA from microbial DNA. The host DNA reads can be used to study the host immune response. The microbial reads are analyzed to identify the composition and abundance of reads of organisms present. The study of RNA can allow for transcriptome-based analysis to identify organisms that are transcriptionally active. Abbreviations: cDNA, complementary DNA; NGS, next-generation sequencing; NA, nucleic acid; 16S rDNA, 16S ribosomal DNA. 42-year-old man with chronic lymphocytic leukemia presented with bilateral hearing loss. He developed neurological deterioration. 1612 of 134 068 968 (0.0012%) reads from brain tissue RNA aligned to astrovirus, no astrovirus reads were obtained from the 6 658 656 reads from CSF. RT-PCR for astrovirus from the brain biopsy Treated empirically with high-dose valacyclovir, broad-spectrum antibiotics, and IVIG. After the NGS analysis revealed astrovirus, the patient was treated with ribavirin and IVIG but eventually passed away. [35] 3 male (aged 63, 63, and 72 years) breeders of variegated squirrels had progressive encephalitis Variegated squirrel 1 bornavirus reads detected in brain samples from all 3 patients. Variegated squirrel bornavirus encephalitis All 3 patients passed away prior to mNGS results. [43] 11-year-old girl from Mexico presented with 4 weeks of headache, back pain, nausea, and emesis. CSF was found to be positive for EBV and HHV7. She was treated with acyclovir and discharged. Two weeks later she presented with back pain and worsening headache. She was rehospitalized with a diagnosis of tuberculosis. 34-year-old Australian man with X-linked agammaglobulinemia suffering from 3 years of meningoencephalitis that defied an etiologic disease despite extensive conventional testing, including brain biopsy. 5 of 25 069 677 (0.00002%) and 2 of 13 661 871 (0.00001%) reads of the CSF and brain biopsy aligned to Cache Valley virus. CVV RT-PCR of the brain biopsy and immunohistochemistry straining of the FFPE brain tissue Chronic viral meningoencephalitis: Cache Valley virus Pooled IVIG was attempted but the patient passed away. [23] 16-year-old boy from Vietnam suddenly became ill with fevers and rigors, followed by back pain, diarrhea, neck stiffness, limb weakness with eventual flaccid paralysis with convulsions and cognitive decline. mNGS was performed on CSF, urine, plasma, and rectal swab specimens. The urine sample was positive for JEV RNA. Seroconversion and PCR analysis confirmed findings. The patient regained consciousness on day 9 of hospitalization, the limb strength gradually returned. [20] 782 35-year-old man with ventricular septal defect admitted with fever of 3 months' duration. Cardiac valve vegetation showed 97% of bacterial reads were genes of Abiotrophia defectiva. Confirmation was not performed. Abiotrophia defectiva endocarditis Patient treated with antibiotics for 4 weeks and discharged. [49] Three patients in central Africa presenting with acute hemorrhagic fever. Sequencing of the third patient's serum yielded 0.029% of reads with nucleotide or protein homology to a novel rhabdovirus. Clinical outcomes not provided. [42] Stool samples positive (n = 22) or negative (n = 5) for Clostridioides (previously Clostridium) difficile were tested by mNGS. C. difficile was found in 86% of known positive samples by mNGS. Additional pathogens were detected in up to 27% of samples. Co-detected pathogens were confirmed by PCR. Clinical outcomes not provided. [ approaches are being developed for mNGS. A recent example is the use of "spike-in"-based calibration to determine total microbial load as a proxy to convert percentage reads in relation to quantitating bacterial burden in colony-forming units (CFU) per milliliter [26] . Another approach to distinguish colonization from infection is to monitor and assess the host immune response. Langelier et al found that expression of a multigene immune response composite metric was significantly increased in hematopoietic cellular transplant patients with confirmed respiratory pathogens relative to those without a defined pathogen. These results suggest that, even in patients who have significant immunosuppression, the immune response may be used as a biomarker of active infection when utilizing host reads from mNGS analysis of respiratory specimens [19] . The capability of unbiased sequencing directly from patient specimens is what makes mNGS an ideal, hypothesis-free diagnostic tool for infectious diseases. However, it also brings challenges as nucleic acid contamination occurs at several steps in the process from specimen acquisition to specimen processing and the environment, making interpretation of results challenging. Samples should be collected with much caution; for example, lumbar punctures to obtain CSF specimens can be contaminated by normal skin microbiota during the procedure. Similarly, surgical specimens may be contaminated during handling of the biopsy [17] . In addition, specimen collection containers are ideally verified to be DNA/RNA free as they too may serve as a source of contaminating nucleic acid. The development and strict adherence of specimen collection guidelines are crucial for reducing risk of contamination introduced at the time of specimen collection [9] . Furthermore, many researchers have shown that most reagents utilized for mNGS also introduce extraneous, unwanted sources of DNA during the sequencing process; this phenomenon is referred to as the "kit-ome" [9] . A study by Salter et al demonstrated that extraneous DNA is ubiquitous in commonly used DNA extraction reagents and other laboratory reagents used for NGS. The contamination can critically impact results obtained from samples, especially those containing low microbial biomass [27, 28] . This becomes particularly relevant when there is a lack of an obvious pathogen (eg, Mycobacterium tuberculosis or JC virus where they are not found as contaminants in reagents or part of normal microbiota) especially for mNGS analysis of CSF specimens where common reagent contaminants can include members of the Enterobacteriaceae or Cutibacterium acnes (previously known as Propionibacterium acnes), making clinical relevance difficult to discern. Thus, it is imperative that a no-template control (a sample [ie, water or extraction buffer] that is run through the entire mNGS procedure) be included in mNGS analyses to determine the nucleic acid background of the reagents used for sequencing. The no-template control can be used when interpreting results to help filter out contaminating background reads. In fact, the no template control has been utilized as part of a cutoff to determine the relevance of mNGS findings from patient specimens. A recent report used a cutoff of ≥10 ratio of the reads per million sample divided by the reads per million of the no-template control from any given taxon (species, genus, or family) [21] . Another approach is to align the reads to the genome of the pathogen to see if the reads span different areas of the genome. If the reads are localized to a restricted area of the genome, the reads are more likely to represent a contaminant, whereas if the reads span the genome, the organism is more likely to represent a true organism detection [29] . Currently, there is no standardized protocol for mNGS. Thus, it is very important for the physician interpreting results to have a good understanding of the scope of the methods being applied as these impact the ability of the assay to detect certain pathogen types and affects interpretation of results. Methods of mNGS can include a DNA-and/or RNA-based approach. If a DNA-based approach is solely applied, pathogen types, except RNA viruses, will be detected. An RNA-based approach is required for detection of RNA viruses and further provides transcriptome-based analysis of other pathogen types and even the host immune response. A DNA approach will indicate what organism(s) are present, but an RNA approach can further reveal what organism(s) are transcriptionally active. Another major factor that will impact results is the type of extraction method utilized in the laboratory. Nucleic acid recovery may not be equal for all pathogen types [30] . For example, mycobacteria require significant cell wall disruption to efficiently lyse the organisms for nucleic acid release. Different extraction methods may also be required for different specimen types [4] . Efficient extraction methods are a critical step to achieve truly unbiased sequencing of a sample. In addition, the limit of detection is important to determine, as a negative mNGS result may simply reflect the high leukocyte count of a sample or low sequencing depth of a specimen rather than the absence of a pathogen. The reported limit of detection of mNGS from synthetic CSF matrix varies by organism type from a low of 0.01 CFU/mL for Cryptococcus neoformans, approximately 9 CFU/mL for Klebsiella pneumoniae and Streptococcus agalactiae, 9.4 copies/mL for cytomegalovirus, 55 organisms/mL for Toxoplasma gondii, and 100 copies/mL of human immunodeficiency virus (HIV) type 1, to a high of 130 CFU/mL of Aspergillus niger for detection [4] . This compares to 10 4-5 CFU/mL for detection of pathogens by special stains directly from a specimen (ie, Gram stain), 10 2-3 CFU/mL for growth in culture, and 10-100 CFU/mL for nucleic acid amplification-based methods [31] . It also varies by specimen type, as the limit of detection of mNGS for hepatitis C virus and HIV from plasma has been reported as high as 1 × 10 4 copies/mL, as determined by quantitative PCR [32] . Use of an internal control is extremely important to identify analytic failures and specimens with unusual cellularity that may result in reduced analytical sensitivity. While a negative mNGS result does not completely rule out an infectious process, adequate recovery of the internal control can indicate the level of sensitivity achieved by the assay for that particular sample [4] . Results will still need to be interpreted within a clinical context. Last, validation of mNGS by individual laboratories at the moment can be time consuming and extremely costly, as significant optimization is required for development, and de novo establishment of performance characteristics is required as there are no currently available US Food and Drug Administration (FDA)-cleared methods, instruments, and/or databases [4] . For example, validation of a single specimen type such as CSF will easily require an investment of more than US$100 000 simply for supply costs, not including technologist time and instrumentation fees. Thus, many hospitals may choose to send testing out to larger reference or commercial laboratories that have the resources to optimize and validate mNGS. Regardless of where testing is being performed, physicians need to have a strong understanding of the methods to appropriately interpret the results. A major bottleneck of mNGS for infectious disease diagnostics is the ability to decipher the data into clinically relevant information to positively impact patient care. The large sums of data generated by mNGS are burdensome in terms of storage and analysis. mNGS data include host reads, which introduces privacy concerns and requires HIPAA (Health Insurance Portability and Accountability Act)-compliant storage tools [33] . Host reads may be removed during data analysis steps, but can also be helpful to confirm a patient's identity to assist in ruling out mislabeling or contamination issues [34] . Rapid bioinformatics tools are required to allow for data analysis to obtain clinically actionable results in a meaningful timeframe. A diversity of data analysis tools exist, most of which first filter out host reads and then taxonomically classify the microbial reads to the most accurate taxonomic level (ie, species/ subspecies level if possible, otherwise a genus-, family-, order-, class-, phylum-, or kingdom-level identification is provided) [4] . Two bioinformatics pipelines have been applied successfully in most clinical studies, the "sequence-based ultrarapid pathogen identification" (SURPI or SURPI+) pipeline and the Kraken pipeline [4, 17, 19-23, 29, 35] . Both of these pipelines rapidly align the sequencing reads to the National Center for Biotechnology Information (NCBI) nucleotide reference database and use taxonomic classification for more accurate read assignments [36, 37] . Bioinformatics programs also need to be straightforward with user-friendly interfaces for incorporation into clinical microbiology laboratories. Currently, most of these analytic tools require a significant degree of bioinformatics expertise that is typically not available in clinical laboratories [38] . Some suggest that many different algorithms using a variety of approaches, such as the use of k-mer, marker, and alignments, are required to analyze the data to ensure the highest sensitivity and specificity for taxonomic classification [9, 39] . Last, curated databases are required as several draft genomes or partial sequences available on NCBI contain erroneous information and can result in false-positive results. False-positive results using noncurated databases can result from low-complexity sequences matching low-quality reads from the sample (ie, computational noise), misannotated species, or contaminants from database entries that also contain reads to human DNA, sequencing adaptors, or vectors. False negatives may occur due to incomplete or lack of taxonomic representation in the databases. Due to these issues, there have been significant efforts put in place to create accurate, regulatory-grade databases, such as the FDA ARGOS database, that can be applied clinically [40] . Currently, the turnaround time for mNGS has been reported to be anywhere from approximately 6 hours to 7 days (average of 48 hours) from specimen receipt depending on the sequencing technology, methods, and bioinformatics programs exploited [9, 22, 25, 41, 42] . In general, mNGS methodologies are labor intensive and require several steps from nucleic acid extraction, library preparation, and sequencing to data analysis. Depending on the sequencing chemistry (read lengths, pairedend vs single-end sequencing, depth of sequencing, or sequencing platforms), it can take up to 48 hours (average of ~ 24 hours) to generate the sequence data alone. Once the sequencing data are generated, rapid bioinformatic pipelines may yield results in as little as 1 hour with significant computational power to support the analysis [17] . mNGS reports can contain >2000 lines in length summarizing the reads from the sample (see Supplementary Data). Figure 3 demonstrates an example of a simplified mNGS Kraken report along with interpretation using a Web-based application tool for visualization of results incorporating heat maps to highlight predominant pathogens and alignment tools useful for result interpretation [29] . Perhaps the greatest challenge for the practicing infectious disease clinician is interpretation of the results generated by the sequencing laboratory. Due to the complexity of results generated from mNGS, some institutions have implemented precision medicine teams. These teams consist of representatives from medical microbiology, computational biology, infectious diseases, and other clinician groups who can discuss the results and provide interpretation of the mNGS results prior to reporting. This approach ensures that the most clinically relevant data are reported. Additionally, in the authors' experience, development of such a team was useful in determining direction of assay development and lobbying the institution for resources. Another approach, which is strongly advised, is to have an experienced laboratory director manually review the results prior to release [21] . SUCCESSFUL APPLICATIONS OF mNGS mNGS directly from clinical specimens came to the forefront when the Chiu laboratory from the University of California, San Francisco (UCSF) applied the methodology to achieve diagnoses in a case of neuroleptospirosis and a case of neuroinvasive astrovirus [22, 35] . In both cases, standard microbial diagnostic techniques were applied, but no pathogens were identified. Unbiased mNGS was applied and successfully identified the infectious agents in these cases. These cases are examples of the power of NGS as a diagnostic tool. Initial applications of mNGS for diagnostics focused on central nervous system infections, mostly chronic infections, and have successfully diagnosed rare [22] , novel [43] , and atypical infectious etiologies [23] of encephalitis. One particular case of chronic Cache Valley virus encephalitis in an Australian patient highlights the ability of mNGS to identify pathogens not previously associated with a clinical phenotype [23] . A single report of the accuracy of mNGS compared to standard methods of 84 previously positive CSF specimens and 21 negative specimens observed a diagnostic sensitivity of 84.3% and specificity of 93.7% following discordant analysis [4] . Some recent articles describe the utility of the assay for detection of respiratory pathogens directly from bronchoalveolar lavage specimens from human stem cell transplant and lung transplant recipients [19, 25] . Table 1 summarizes the successful applications of mNGS in the literature to date (July 2017). All these studies have been performed using short read data (second-generation Illumina sequencing), with 2 exceptions. Recently, publications by Pendleton et al and Greninger et al demonstrated the utility of mNGS using the affordable, portable MinION sequencer (third-generation sequencing) that generates long reads with sequencing analysis that can occur in real time [25, 41] . The mNGS analysis of specimens by Pendleton et al resulted in a Figure 3 . Example of results output and bioinformatics analysis tools for metagenomic next-generation sequencing data. A, A simplified Kraken report showing the number and percentage of sequence reads and their alignment identification using Kraken for a cerebrospinal fluid (CSF) specimen from a patient diagnosed with JC virus encephalitis [17] . The overall Kraken report summarizing the data from the CSF specimen is >2000 line listings long (see Supplementary Data). Of note, Escherichia coli, Pseudomonas putida group, and Propionibacterium acnes (now Cutibacterium acnes) were considered reagent contaminants in this case as they were observed in the no-template control. B-D, Analysis modes of the Web-based Pavian program, a straightforward interface to analyze and compare complex metagenomics datasets. B, The number of sequence reads matching each taxa of interest are shown for the sample. Of note, almost all the virus reads align to JC polyomavirus. C, A heat map approach showing the percentage of microbially matched reads across multiple samples allowing for sample comparison. D, An interactive alignment tool showing the fold coverage of the reads over the whole JC virus genome [29] . more rapid turnaround time of the pathogens causing lower respiratory tract infections than standard culture methods [25] . For the most part, the successful application of mNGS has occurred for diagnoses of severe, insidious infections or has been performed in retrospective studies compared to standardof-care results. Ideally, this technology would be applied in real time as an adjunct to current SoC testing. mNGS is currently being offered as a billable laboratory-developed test by both clinical and commercial laboratories. The question is, when should this rather expensive test be considered for clinical care? Based on the available literature, mNGS could be considered when SoC testing is unrevealing and can be used as a last resort effort to try to discern an infectious process. Alternatively, it may be considered for critically ill or severely immunocompromised patients where achieving a timely diagnosis is imperative for improved outcomes. Importantly, mNGS does not replace current SoC methods, but should rather be used as an adjunct to these methods. At this point in time, this question is still actively under investigation and further evidence is required to establish the use of mNGS in routine clinical care. CONCLUSIONS mNGS has emerged as a promising single, universal pathogen methodology for infectious disease diagnostics. In addition, mNGS will further be developed in years to come to evaluate antimicrobial resistance genes, strain typing, pathogen evolution, immune response to offending pathogens, and detection of virulence genes. As mNGS methods are still being developed and NGS technologies are rapidly evolving, there are still challenges ahead in terms of data interpretation and patient privacy. Infectious disease clinicians and other treating physicians can actively participate in the quality management of NGS diagnostic applications by appreciating the complexities and nuances of the methodologies being applied and ensuring that steps, as discussed in this and other reviews, are implemented to generate meaningful results beneficial to patient care. Supplementary materials are available at Clinical Infectious Diseases online. Consisting of data provided by the authors to benefit the reader, the posted materials are not copyedited and are the sole responsibility of the authors, so questions or comments should be addressed to the corresponding author. Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study Prospective evaluation of a matrix-assisted laser desorption ionization-time of flight mass spectrometry system in a hospital clinical microbiology laboratory for identification of bacteria and yeasts: a bench-by-bench study for assessing the impact on time to identification and cost-effectiveness Beyond viruses: clinical profiles and etiologies associated with encephalitis Professional Practice Committee and Committee on Laboratory Practices of the American Society for Microbiology; Microbiology Resource Committee of the College of American Pathologists. Validation of metagenomic next-generation sequencing tests for universal pathogen detection Origins of the E. coli strain causing an outbreak of hemolytic-uremic syndrome in Germany Large-scale genomic sequencing of extraintestinal pathogenic Escherichia coli strains Whole genome sequencing indicates Corynebacterium jeikeium comprises 4 separate genomospecies and identifies a dominant genomospecies among clinical isolates Coinfection of Fusobacterium nucleatum and Actinomyces israelii in mastoiditis diagnosed by next-generation DNA sequencing Precision metagenomics: rapid metagenomic analyses for infectious disease diagnostics and public health surveillance Making the leap from research laboratory to clinic: challenges and opportunities for next-generation sequencing in infectious disease diagnostics Third generation sequencing technologies applied to diagnostic microbiology: benefits and challenges in applications and data analysis A decade's perspective on DNA sequencing technology Sequencing technologies-the next generation An evaluation of the accuracy and speed of metagenome analysis tools Application of next generation sequencing in clinical microbiology and infection prevention The role of whole genome sequencing in antimicrobial susceptibility testing of bacteria: report from the EUCAST Subcommittee Next-generation sequencing in neuropathologic diagnosis of infections of the nervous system Depletion of human DNA in spiked clinical specimens for improvement of sensitivity of pathogen detection by next-generation sequencing Metagenomic next-generation seqeuceng detects pulmonary pathogens in hematopoietic cellular transplant patients with acute respiratory illnesses Central nervous system infection diagnosis by next-generation sequencing: a glimpse into the future? Neurobrucellosis: unexpected answer from metagenomic next-generation sequencing Actionable diagnosis of neuroleptospirosis by next-generation sequencing A novel cause of chronic viral meningoencephalitis: Cache Valley virus Virome genomics: a tool for defining the human virome Rapid pathogen identification in bacterial pneumonia using real-time metagenomics Adjusting microbiome profiles for differences in microbial load by spike-in bacteria The perils of pathogen discovery: origin of a novel parvovirus-like hybrid genome traced to nucleic acid extraction spin columns Reagent and laboratory contamination can critically impact sequence-based microbiome analyses Pavian: interactive analysis of metagenomics data for microbiomics and pathogen identification Comparative evaluation of DNA extraction methods from feces of multiple host species for downstream next-generation sequencing Multicenter evaluation of BioFire FilmArray meningitis/encephalitis panel for detection of bacteria, viruses, and yeast in cerebrospinal fluid specimens Presence of human hepegivirus-1 in a cohort of people who inject drugs Routes for breaching and protecting genetic privacy Microbiome privacy risk Diagnosis of neuroinvasive astrovirus infection in an immunocompromised adult with encephalitis by unbiased next-generation sequencing A cloud-compatible bioinformatics pipeline for ultrarapid pathogen identification from next-generation sequencing of clinical samples Kraken: ultrafast metagenomic sequence classification using exact alignments Role of clinicogenomics in infectious disease diagnostics and public health microbiology Geospatial resolution of human and bacterial diversity with city-scale metagenomics Database for Reference Grade Microbial Sequences (FDA-ARGOS) Rapid metagenomic identification of viral pathogens in clinical samples by real-time nanopore sequencing analysis Comprehensive diagnosis of bacterial infection associated with acute cholecystitis using metagenomic approach A variegated squirrel bornavirus associated with fatal human encephalitis Clinical metagenomic identification of Balamuthia mandrillaris encephalitis and assembly of the draft genome: the continuing case for reference genome sequencing Hepatitis E virus-associated meningoencephalitis in a lung transplant recipient diagnosed by clinical metagenomic sequencing Diagnosis of fatal human case of mosquito-borne St. Louis encephalitis virus infection diagnosed by metagenomic sequencing Illuminating uveitis: metagenomic deep sequencing identifies common and rare pathogens Coinfections of Zika and Chikungunya viruses in Bahia, Brazil, identified by metagenomic next-generation sequencing Metagenomic analysis for detecting pathogens in culture-negative infective endocarditis A novel rhabdovirus associated with acute hemorrhagic fever in central Africa Metagenomic approach for identification of the pathogens associated with diarrhea in stool specimens Potential conflicts of interest. K. C. C. reports grants from Accelerate Diagnostics, Curetis, BD Diagnostics, and GenePOC; personal fees from Roche Molecular, McGraw-Hill, American Society for Microbiology, and Elsevier. P. J. S. reports grants from Accelerate Diagnostics, BD Diagnostics, bioMérieux, Cellex, Check-Points Diagnostics, BV, and Hardy Diagnostics; and personal fees from the American Society for Microbiology and Accelerate Diagnostics. S. M. has a patent for the SURPI pipeline issued to UCSF, a patent for microbial standard reference materials for pathogen detection pending to UCSF, and a patent for historic contaminant database for mNGS applications pending to UCSF. All authors have submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Conflicts that the editors consider relevant to the content of the manuscript have been disclosed.